A carregar...
Euglycemic DKA (euDKA) as a presentation of COVID‐19
COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.
Na minha lista:
| Publicado no: | Clin Case Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753533/ https://ncbi.nlm.nih.gov/pubmed/33362928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3540 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|